Tonix Pharmaceuticals Holding Corp
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.561
- Today's High:
- $0.5899
- Open Price:
- $0.57
- 52W Low:
- $0.29
- 52W High:
- $7.712
- Prev. Close:
- $0.57
- Volume:
- 351405
Company Statistics
- Market Cap.:
- $36.92 million
- Book Value:
- 2.709
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -30.03%
- Return on Equity TTM:
- -51.76%
Company Profile
Tonix Pharmaceuticals Holding Corp had its IPO on 2012-05-10 under the ticker symbol TNXP.
The company operates in the Healthcare sector and Biotechnology industry. Tonix Pharmaceuticals Holding Corp has a staff strength of 117 employees.
Stock update
Shares of Tonix Pharmaceuticals Holding Corp opened at $0.57 at the start of the last trading session i.e. 2023-03-24.
The stocks traded within a range of $0.56 - $0.59, and closed at $0.58.
This is a +1.26% increase from the previous day's closing price.
A total volume of 351,405 shares were traded at the close of the day’s session.
In the last one week, shares of Tonix Pharmaceuticals Holding Corp have slipped by -3.8%.
Tonix Pharmaceuticals Holding Corp's Key Ratios
Tonix Pharmaceuticals Holding Corp has a market cap of $36.92 million, indicating a price to book ratio of 0.0865 and a price to sales ratio of 0.
In the last 12-months Tonix Pharmaceuticals Holding Corp’s revenue was $0 with a gross profit of $0 and an EBITDA of $-110838000. The EBITDA ratio measures Tonix Pharmaceuticals Holding Corp's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Tonix Pharmaceuticals Holding Corp’s operating margin was 0% while its return on assets stood at -30.03% with a return of equity of -51.76%.
In Q4, Tonix Pharmaceuticals Holding Corp’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Tonix Pharmaceuticals Holding Corp’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-3.1 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Tonix Pharmaceuticals Holding Corp’s profitability.
Tonix Pharmaceuticals Holding Corp stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 1.1005. Its price to sales ratio in the trailing 12-months stood at 0.
Tonix Pharmaceuticals Holding Corp stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $225.69 million
- Total Liabilities
- $18.18 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $4.67 million
- Dividend Payout Ratio
- 0%
Tonix Pharmaceuticals Holding Corp ended 2023 with $225.69 million in total assets and $0 in total liabilities. Its intangible assets were valued at $225.69 million while shareholder equity stood at $207.18 million.
Tonix Pharmaceuticals Holding Corp ended 2023 with $0 in deferred long-term liabilities, $18.18 million in other current liabilities, 76000.00 in common stock, $-470038000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $0 and cash and short-term investments were $0. The company’s total short-term debt was $432,000 while long-term debt stood at $0.
Tonix Pharmaceuticals Holding Corp’s total current assets stands at $130.78 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $8.07 million and inventory worth $0.
In 2023, Tonix Pharmaceuticals Holding Corp's operating cash flow was $0 while its capital expenditure stood at $4.67 million.
Comparatively, Tonix Pharmaceuticals Holding Corp paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- $0.58
- 52-Week High
- $7.712
- 52-Week Low
- $0.29
- Analyst Target Price
- $6.33
Tonix Pharmaceuticals Holding Corp stock is currently trading at $0.58 per share. It touched a 52-week high of $7.712 and a 52-week low of $7.712. Analysts tracking the stock have a 12-month average target price of $6.33.
Its 50-day moving average was $0.9 and 200-day moving average was $0.93 The short ratio stood at 1.41 indicating a short percent outstanding of 0%.
Around 4.5% of the company’s stock are held by insiders while 1540.8% are held by institutions.
Frequently Asked Questions About Tonix Pharmaceuticals Holding Corp
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company’s infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.